Regeneron stock recovered and closed higher Monday after the drugmaker preannounced light sales of a high-dose version of its blockbuster eye drug, Eylea. Please watch the video at Investors.com ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

M.D., Ph.D., was asked about disappointing sales of high-dose Eylea. “I’d be happier to talk about the pipeline,” Schleifer said. Earlier on Monday, Regeneron shared preliminary results from ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

“Impressively, the latest three-year EYLEA HD results show a substantial portion of patients were able to sustain visual and anatomic benefits with only two doses a year. This adds yet another ...

Primarily, the lower-than-expected sales figures for Eylea’s high dose in the fourth quarter raised concerns, as revenues fell short of both his and market consensus estimates. This ...

Brokerage slashed price target to $738 from $1130. The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea ...

Regular dose Eylea sales in the US were $1.2 billion, or an 11% year-on-year decline, while Eylea high-dose sales in the US were $305 million, or 148% year-on-year growth. Although Roche’s ...